1. Home
  2. KLRS

as 08-26-2025 3:33pm EST

$
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.

Founded: 2019 Country:
United States
United States
Employees: N/A City: PALO ALTO
Market Cap: 46.0M IPO Year: N/A
Target Price: N/A AVG Volume (30 days): 47.9K
Analyst Decision: Buy Number of Analysts: 1
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -6.99 EPS Growth: N/A
52 Week Low/High: $2.14 - $24.15 Next Earning Date: 08-13-2025
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

KLRS Daily Stock ML Predictions

Share on Social Networks: